Search

Your search keyword '"Hindes, Robert"' showing total 16 results
Start Over Author "Hindes, Robert"
16 results on '"Hindes, Robert"'

1. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Author

Lawitz, Eric, Lalezari, Jay P, Hassanein, Tarek, Kowdley, Kris V, Poordad, Fred F, Sheikh, Aasim M, Afdhal, Nezam H, Bernstein, David E, DeJesus, Edwin, Freilich, Bradley, Nelson, David R, Dieterich, Douglas T, Jacobson, Ira M, Jensen, Donald, Abrams, Gary A, Darling, Jama M, Rodriguez-Torres, Maribel, Reddy, K Rajender, Sulkowski, Mark S, Bzowej, Natalie H, Hyland, Robert H, Mo, Hongmei, Lin, Ming, Mader, Michael, Hindes, Robert, Albanis, Efsevia, Symonds, William T, Berrey, Michelle M, and Muir, Andrew

Published
2013
Full Text
View/download PDF

2. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

Author

Pol, Stanislas, Ghalib, Reem H, Rustgi, Vinod K, Martorell, Claudia, Everson, Greg T, Tatum, Harvey A, Hézode, Christophe, Lim, Joseph K, Bronowicki, Jean-Pierre, Abrams, Gary A, Bräu, Norbert, Morris, David W, Thuluvath, Paul J, Reindollar, Robert W, Yin, Philip D, Diva, Ulysses, Hindes, Robert, McPhee, Fiona, Hernandez, Dennis, Wind-Rotolo, Megan, Hughes, Eric A, and Schnittman, Steven

Published
2012
Full Text
View/download PDF

3. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Author

Sulkowski, Mark S., Gardiner, David F., Rodriguez-Torres, Maribel, Reddy, Rajender K., Hassanein, Tarek, Jacobson, Ira, Lawitz, Eric, Lok, Anna S., Hinestrosa, Federico, Thuluvath, Paul J., Schwartz, Howard, Nelson, David R., Everson, Gregory T., Eley, Timothy, Wind-Rotolo, Megan, Huang, Shu-Pang, Gao, Min, Hernandez, Dennis, McPhee, Fiona, Sherman, Diane, Hindes, Robert, Symonds, William, Pasquinelli, Claudio, and Grasela, Dennis M.

Published
2014
Full Text
View/download PDF

5. Once Daily Sofosbuvir (GS-7977) plus PEG/RBV: High Early Response Rates Are Maintained During Post-Treatment Follow-Up In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection in the ATOMIC Study: 230

Author

Hassanein, Tarek, Lawitz, Eric, Crespo, Israel, Davis, Mitchell, DeMicco, Michael P., Nelson, David R., Bernstein, David Eric, Afdhal, Nezam, Jacobson, Ira M., Vierling, John M., Gordon, Stuart C., Anderson, Jane, Hyland, Robert H., Hindes, Robert, Symonds, William T., Albanis, Efsevia, Arora, Sanjeev, and Kowdley, Kris V.

Published
2012

9. Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C

Author

Bronowicki, Jean-Pierre, primary, Pol, Stanislas, additional, Thuluvath, Paul J, additional, Larrey, Dominique, additional, Martorell, Claudia T, additional, Rustgi, Vinod K, additional, Morris, David W, additional, Younes, Ziad, additional, Fried, Michael W, additional, Bourlière, Marc, additional, Hézode, Christophe, additional, Reddy, K Rajender, additional, Massoud, Omar, additional, Abrams, Gary A, additional, Ratziu, Vlad, additional, He, Bing, additional, Eley, Timothy, additional, Ahmad, Alaa, additional, Cohen, David, additional, Hindes, Robert, additional, McPhee, Fiona, additional, Reilly, Bridget, additional, Mendez, Patricia, additional, and Hughes, Eric, additional

Published
2013
Full Text
View/download PDF

10. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

Author

Kowdley, Kris V, primary, Lawitz, Eric, additional, Crespo, Israel, additional, Hassanein, Tarek, additional, Davis, Mitchell N, additional, DeMicco, Michael, additional, Bernstein, David E, additional, Afdhal, Nezam, additional, Vierling, John M, additional, Gordon, Stuart C, additional, Anderson, Jane K, additional, Hyland, Robert H, additional, Dvory-Sobol, Hadas, additional, An, Di, additional, Hindes, Robert G, additional, Albanis, Efsevia, additional, Symonds, William T, additional, Berrey, M Michelle, additional, Nelson, David R, additional, and Jacobson, Ira M, additional

Published
2013
Full Text
View/download PDF

11. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

Author

Chang, Ting-Tsung, primary, Liaw, Yun-Fan, additional, Wu, Shun-Sheng, additional, Schiff, Eugene, additional, Han, Kwang-Hyub, additional, Lai, Ching-Lung, additional, Safadi, Rifaat, additional, Lee, Samuel S., additional, Halota, Waldemar, additional, Goodman, Zachary, additional, Chi, Yun-Chan, additional, Zhang, Hui, additional, Hindes, Robert, additional, Iloeje, Uchenna, additional, Beebe, Suzanne, additional, and Kreter, Bruce, additional

Published
2010
Full Text
View/download PDF

12. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Author

Sherman, Morris, primary, Yurdaydin, Cihan, additional, Sollano, Jose, additional, Silva, Marcelo, additional, Liaw, Yun–Fan, additional, Cianciara, Janusz, additional, Boron–Kaczmarska, Anna, additional, Martin, Paul, additional, Goodman, Zachary, additional, Colonno, Richard, additional, Cross, Anne, additional, Denisky, Gail, additional, Kreter, Bruce, additional, and Hindes, Robert, additional

Published
2006
Full Text
View/download PDF

13. A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Author

Chang, Ting–Tsung, primary, Gish, Robert G., additional, Hadziyannis, Stephanos J., additional, Cianciara, Janusz, additional, Rizzetto, Mario, additional, Schiff, Eugene R., additional, Pastore, Giuseppe, additional, Bacon, Bruce R., additional, Poynard, Thierry, additional, Joshi, Shobha, additional, Klesczewski, Kenneth S., additional, Thiry, Alexandra, additional, Rose, Ronald E., additional, Colonno, Richard J., additional, and Hindes, Robert G., additional

Published
2005
Full Text
View/download PDF

16. Randomized Study of Asunaprevir plus Pegylated Interferon-a and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C

Author

Bronowicki, Jean-Pierre, Pol, Stanislas, Thuluvath, Paul J, Larrey, Dominique, Martorell, Claudia T, Rustgi, Vinod K, Morris, David W, Younes, Ziad, Fried, Michael W, Bourlière, Marc, Hézode, Christophe, Reddy, K Rajender, Massoud, Omar, Abrams, Gary A, Ratziu, Vlad, He, Bing, Eley, Timothy, Ahmad, Alaa, Cohen, David, Hindes, Robert, McPhee, Fiona, Reilly, Bridget, Mendez, Patricia, and Hughes, Eric

Abstract

Background Asunaprevir is a selective NS3 protease inhibitor with in vitroactivity against HCV genotypes 1 and 4.Methods In this Phase IIa double-blind study, treatment-naive HCV genotype-1-infected patients in the United States and France were randomly assigned 1:1:1:1 to placebo or asunaprevir 200 mg twice daily, 600 mg twice daily or 600 mg once daily in combination with pegylated interferon (PEG-IFN)-a2a and ribavirin for 48 weeks. The primary efficacy end point was undetectable HCV RNA at weeks 4 and 12 (extended rapid virological response [eRVR]). Other end points included safety and undetectable HCV RNA at 24 weeks post-treatment (24-week sustained virological response [SVR24]).Results A total of 47 patients were randomized and treated. eRVR was achieved by 75% (9/12), 75% (9/12) and 92% (11/12) of patients in the asunaprevir 200 mg twice-daily, 600 mg twice-daily and 600 mg once-daily groups, respectively, versus 0% (0/11) in the placebo group. Corresponding SVR24rates were 83% (10/12), 83% (10/12) and 92% (11/12) in the asunaprevir groups and 46% (5/11) in the placebo group. There was no virological breakthrough in any asunaprevir group. Following the 12-week analysis, the 600 mg doses were reduced to 200 mg twice daily because of a greater frequency of transaminase elevations at the 600 mg dose. The most common grade 3–4 laboratory abnormalities were consistent with those reported for PEG-IFN and ribavirin.Conclusions Asunaprevir plus PEG-IFN and ribavirin achieved higher response rates than placebo plus PEG-IFN and ribavirin, with a tolerable adverse event profile at the 200 mg twice-daily dose. This dose is being evaluated in the Phase IIb and Phase III studies.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results